Evidence map›Paper›PMID 37810752›Full record

ArticleMaterials today. Bio2023

HER2-targeting two-dimensional black phosphorus as a nanoplatform for chemo-photothermal therapy in breast cancer.

Yuanke Liang, Jinxing Liu, Cong Zhao, Hexing Sun, Kaiyuan Huang, Qin Xie, De Zeng, Haoyu Lin, Benqing Zhou

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yuanke LiangDepartment of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515000, China.
Jinxing LiuDepartment of Biomedical Engineering, College of Engineering, Shantou University, Shantou, 515063, China.
Cong ZhaoDepartment of Biomedical Engineering, College of Engineering, Shantou University, Shantou, 515063, China.
Hexing SunDepartment of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515000, China.
Kaiyuan HuangDepartment of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515000, China.
Qin XieCancer Hospital of Shantou University Medical College, Shantou, 515031, China.
De ZengCancer Hospital of Shantou University Medical College, Shantou, 515031, China.
Haoyu LinDepartment of Thyroid and Breast Surgery, Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, 515000, China.
Benqing ZhouDepartment of Biomedical Engineering, College of Engineering, Shantou University, Shantou, 515063, China.
Shantou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab (Tmab) targeted therapy or its combination with chemotherapy is normally insufficient to elicit a comprehensive therapeutic response owing to the inherent or acquired drug resistance and systemic toxicity observed in highly invasive HER2-positive breast cancer. In this study, we propose a novel approach that integrates photothermal therapy (PTT) with targeted therapy and chemotherapy, thereby achieving additive or synergistic therapeutic outcomes. We utilize PEGylated two-dimensional black phosphorus (2D BP) as a nanoplatform and photothermal agent to load chemotherapeutic drug mitoxantrone (MTO) and conjugate with Tmab (BP-PEG-MTO-Tmab). The

Indexed as

Breast cancerChemotherapyPhotothermal therapyTrastuzumabTwo-dimensional black phosphorus

Identifiers

PMID37810752
PMCPMC10550767
OpenAlexW4386955153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.